Flora Peyvandi Shares BIC 2025 Coverage of Hemostasis & Thrombosis: 10 Posts Not To Miss
Flora Peyvandi, Professor of Internal Medicine-Hemostasis and Thrombosis Unit, University of Milan, former President of ISTH, shared on X:
Flora Peyvandi shared BIC 2025 Coverage of latest research on Hemostasis and Thrombosis fresh from the conference:
1.‘‘Wolfgang Miesbach reports the safety of HA and HB gene therapies after 5 and 4 years respectively”
2.”David Lilicrap reports the interindividual variability of gene therapy in Hemophilia at BIC2025”
3.‘‘David Lilicrap reports data on long term safety of HA gene therapy”
4.”Alessio Cantore at Bic 2025 reporting where we are standing with lentiviral gene therapy in Hemophilia”
5.”Naldini group showed clearly they are ready to go through clinical trial phase 1 for HB with lenti viral vector and what’s missing is Funding.
Why that’s happening? No more interest in GT in Hemophilia even for the cure?”
6.”Very interesting data on gene therapy as the ITI to reverse the anti factor inhibitors in mice with anti FIX inhibitors was successful bic 2025.
Data from Dr Herzog Indiana University”
7.”New gene therapy clinical trial on FVII severe deficiency by Amit Nathwani. Look forward for that!”
8.”Amy Shapiro reports a new DDAP molecule to treat patients with VWD type 1.
This is a great news due to discontinuation of intranasal Desmopressin and it shortage.
This formulation is available in US”
9.”A single dose of VGA039 in 10 patients with VWD inhibiting PS , showed good efficacy with no safety issue reported by Carolyn Millar”
10.”Michela Milani should how they created a shielded lentiviral vector to reduce the immunogenicity against FVIII in mice”
More from BIC 2025 featured in Hemostasis Today.
-
Sep 14, 2025, 11:17Isabelle Mahé on Reduced Dose Apixaban for Cancer-Associated VTE: API-CAT Trial Results
-
Sep 13, 2025, 13:32Beta Thalassemia Major After Splenectomy: Setareh Sheikhi Reports Striking nRBC Surge Reports Striking nRBC Surge
-
Sep 13, 2025, 13:26Global Blood and Plasma Collections and Use 2023–2024: Trends, Regulations, and Market Insights
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 14, 2025, 14:36Lp(a) Testing in Primary Prevention: Cost-Effective Strategy to Reduce Cardiovascular Risk
-
Sep 14, 2025, 12:37Ivan Budnik Highlights New Framework for Thrombus Resolution Analysis in Mouse IVC Stenosis Model
-
Sep 14, 2025, 04:16F8 Gene Variants Affect Desmopressin Response in Female Hemophilia A Carriers
-
Sep 13, 2025, 13:35Michael Makris on Rising Malignancy Concerns After Hemophilia Gene Therapy: Key Challenges Highlighted in NEJM
-
Sep 13, 2025, 13:20Giulia Simini: Our Review on the Hepatic Life Cycle of AAV is Now Available in JTH
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 14, 2025, 06:39Abdul Mannan on Factor VIII Aurora: First Natural Gain-of-Function Mutation in Haemophilia A
-
Sep 13, 2025, 13:34Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 13, 2025, 06:49Emna Gouider Belhadjali on the Role of NMOs in Advocating for Equitable Access to Diagnosis for WGBDs
-
Sep 12, 2025, 09:30Arun V J Explains How Blood Donation Rules Differ Worldwide and Why Your Donation Saves Lives Everywhere